145JPY
4.12 BJPY
54.64 BJPY
11.75 M
About TORII PHARMACEUTICAL CO
Sector
Headquarters
Tokyo
Employees (FY)
583
Website
Founded
1872
ISIN
JP3635800000
FIGI
BBG000BCWSL0
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. Its products are mainly used for renal diseases and hemodialysis, human immunodeficiency virus (HIV), skin diseases, and allergies. These include Riona, Remitch, Kayexalate, Corectim, Antebate, Cedarcure, and Miticure. The company was founded by Tokubei Torii in 1872 and is headquartered in Tokyo, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4551 is 3790.00 JPY — it has decreased by 2.70% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange TORII PHARMACEUTICAL CO stocks are traded under the ticker 4551.
TORII PHARMACEUTICAL CO is going to release the next earnings report on Apr 26, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for TORII PHARMACEUTICAL CO has a max estimate of 4700.00 JPY and a min estimate of 4000.00 JPY.
Yes, you can track TORII PHARMACEUTICAL CO financials in yearly and quarterly reports right on TradingView.
Like other stocks, 4551 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TORII PHARMACEUTICAL CO stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 583.00 employees. See our rating of the largest employees — is TORII PHARMACEUTICAL CO on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TORII PHARMACEUTICAL CO EBITDA is 5.50 B JPY, and current EBITDA margin is 9.65%. See more stats in TORII PHARMACEUTICAL CO financial statements.